Supplemental material
Future Oncology
Volume 20, 2024 - Issue 13
Short Communication
Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer
Keith A Betts1 Health Economics & Outcome Research, Analysis Group Inc., Los Angeles, CA90071, USACorrespondence[email protected]
https://orcid.org/0000-0002-3088-7453
https://orcid.org/0000-0002-3088-7453, Sophie Gao1 Health Economics & Outcome Research, Analysis Group Inc., Los Angeles, CA90071, USAhttps://orcid.org/0009-0007-3685-2319
https://orcid.org/0009-0007-3685-2319, Saurabh Ray2 Health Economics & Outcome Research, Bristol Myers Squibb, Lawrenceville, NJ08648, USAhttps://orcid.org/0009-0000-8813-2742
https://orcid.org/0009-0000-8813-2742 &